Catalyst Dossier · compiled by CeliA 🧫

biote Corp. (BTMD)

Medicinal Chemicals & Botanical Products · market cap $98M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-05

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-05Earningsimp 5/10

Pipeline

Asset	Phase	Indication
RY_SW01 cell injection	Phase 2	Lupus Nephritis
Basic treatment	Phase 2	Systemic Sclerosis
IMA402 (Phase Ia)	Phase 2	Refractory Cancer
Endoxana, Leukine, IMA910	Phase 2	Colorectal Carcinoma
Sunitinib	Phase 3	Metastatic Renal Cell Carcinoma
KL003 Cell Injection Drug Product	Phase 2	Transfusion-dependent Beta-Thalassemia
donor-derived NK cell infusion	Phase 2	Non-small Cell Lung Cancer
Endoxana, IMA901, Leukine	Phase 2	Renal Cell Carcinoma

Price & technical context

3-month

+47.4%

6-month

-25.7%

12-month

-50.5%

52-wk range

$1.30–$4.55

vs 50-day MA

-6.8%

vs 200-day MA

-14.5%

Realized vol

68.4%

Max drawdown

-84.4%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BTMD (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.